Biohealx for fistula. Jul 4, 2024 · Signum Surgical has secured De Novo clearance...
Biohealx for fistula. Jul 4, 2024 · Signum Surgical has secured De Novo clearance from the US Food and Drug Administration (FDA) for its BioHealx technology for anal fistula treatment. The implant closes the fistula tract without disrupting the anorectal anatomy. The implant is placed using a pre-loaded, single-use, disposable delivery device that rotates the helical implant into the soft tissue surrounding the fistula tract at its source within the sphincter muscle. Post Aug 5, 2025 · A significant advancement in complex anal fistula treatment, the BioHealx implant functions as a temporary scaffold for healing and fistula closure. The BioHealx delivery device is a sterile single-use, disposable delivery device that rotates the implant into the soft tissue surrounding the internal opening of the fistula tract. Background This is the first in human assessment of the BioHealx® assisted fistula treatment (BAFT) procedure for the pri-mary healing rate of non-branching transsphincteric fistula in ano. The BAFT procedure consists of compression apposition closure of the lumen of the fistula tract from the internal opening across the transsphincteric length of the fistula tract with a bioabsorbable The BioHealx device safely closes anal fistulas with a bioabsorbable implant that creates tissue apposition for primary healing, reducing lengthy and costly repeat procedures and diminishing the Jul 3, 2024 · Signum Surgical announced today that the FDA granted de novo clearance for its BioHealx technology for treating anal fistula. Its unique helical coil design promotes compression-based tissue healing, supporting the sphincter’s integrity—an area where traditional treatments often fail. Jul 3, 2024 · Novel surgical option for the treatment of anal fistula, a painful and debilitating colorectal condition Milestone follows recent completion of clinical trial evaluating the safety and efficacy of the device FDA clearance paves the way for BioHealx™ commercialization 03 July 2024, Galway, Ireland | Signum Surgical (‘Signum’ or ‘the Company’), a medical technology company developing . Aug 17, 2025 · The BioHealx device, developed by Signum Surgical, offers a less-invasive route to treating complex anal fistulas. May 12, 2025 · The BioHealx® device is a novel bioabsorbable implant made from PLGA 8218, designed to close the internal opening of the fistula while maintaining external drainage during healing. May 13, 2025 · The BioHealx® device is an innovative bioabsorbable implant designed to close the internal opening of the fistula while allowing for external drainage during healing. The BioHealx implant is designed as a sterile, single use helical, barbed bioabsorbable implant intended to promote healing by primary intention. The Signum Surgical BioHealx implant is a helical, barbed absorbable implant that is placed around the fistula tract to close it within the sphincter muscle by tissue apposition. BioHealx is a single-use, bioabsorbable implant. It is designed for a minimally invasive procedure to treat anal fistula, a significant development in colorectal disease management. May 6, 2025 · Abstract Background: This is the first in human assessment of the BioHealx® assisted fistula treatment (BAFT) procedure for the primary healing rate of non-branching transsphincteric fistula in ano. fqo fby nbcmz tvsyh dunhe
